sponsored
PatientsVille.com Logo

PatientsVille

Vaginal Bleeding Medical Research Studies

Up-to-date List of Vaginal Bleeding Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Vaginal Bleeding Medical Research Studies

Rank Status Study
1 Unknown  Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern
Condition: Vaginal Bleeding
Interventions: Device: Lapcone;   Procedure: laparoscopic supracervical hysterectomy
Outcome Measures: Occurrence of Vaginal Bleeding 12 months after the procedure.;   Patient satisfaction 12 months after the procedure (10-point analogue scale).
2 Unknown  Progesterone for First Trimester Vaginal Bleeding
Conditions: Threatened Abortion;   Pre-Eclampsia;   Abruptio Placentae;   Fetal Growth Retardation;   Premature Birth
Interventions: Drug: dihydroxyprogesterone caproate;   Drug: Placebo
Outcome Measures: adverse pregnancy outcomes;   Uterine artery blood flow velocimetry;   Placental pathological examination
3 Recruiting Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
Condition: Menstruation Disturbances
Interventions: Drug: Tamoxifen;   Drug: Placebo
Outcome Measures: Bleeding days;   Satisfaction;   Ovulation
4 Recruiting Screening To Obviate Preterm Birth
Conditions: Preterm Labor;   Preterm Contractions,;   Abdominal Cramping;   Back Pain;   Vaginal Pressure;   Vaginal Bleeding
Intervention:
Outcome Measures: Preterm birth;   Early preterm birth
5 Unknown  Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks
Conditions: Induced Abortion;   Abortion Techniques;   Mifepristone;   Misoprostol
Interventions: Drug: Mifepristone;   Drug: Misoprostol
Outcome Measures: Initial cervical dilation at the time of surgical abortion;   Additional cervical dilation required to complete abortion procedure;   Time to conduct procedure;   Percentage of patients who report nausea, vomiting, diarrhea, and Vaginal Bleeding;   Preoperative, intraoperative, and postoperative pain score;   Surgeon's difficulty rating of procedure;   Complications of procedure
6 Recruiting Electronic Catheter Stethoscope
Conditions: Pelvic Organ Prolapse;   Gynecologic Cancers;   Uterine Leiomyomata;   Adenomyosis;   Endometrial Hyperplasia;   Other Abnormal Uterine and Vaginal Bleeding;   Pelvic Mass;   Pelvic Pain
Intervention:
Outcome Measures: bladder and ureter sounds during pelvic surgery.;   changes from baseline bladder and ureteral function sounds
7 Recruiting Progesterone and Second Trimester Bleeding
Conditions: Antepartum Bleeding;   Preterm Birth
Interventions: Drug: micronized progesterone 200 mg (Utrogestan);   Drug: placebo
Outcome Measures: Incidence of spontaneous preterm birth - before 37 weeks.;   Maternal and fetal outcomes
8 Not yet recruiting Vaginal Creams to Reduce Vaginal Erosion in Pessary Users
Conditions: Atrophy of Vagina;   Vaginal Ulceration;   Vaginitis
Interventions: Drug: Estradiol;   Other: placebo
Outcome Measures: Vaginal erosion;   Reason for Discontinuation of pessary based on style of pessary;   Patient satisfaction with Pessary (Pelvic Floor Distress Inventory (PFDI);   vaginal discharge/vaginitis
9 Not yet recruiting Ulipristal for Endometriosis-related Pelvic Pain
Condition: Endometriosis
Intervention: Drug: Ulipristal
Outcome Measures: Pelvic Pain;   Vaginal bleeding;   Pain with sexual intercourse;   Serum hormone levels
10 Unknown  Pelvic Examination in Pregnancy
Conditions: Early Pregnancy Bleeding;   Abdominal Pain
Interventions: Procedure: No Pelvic Exam;   Procedure: Pelvic Examination
Outcome Measures: Composite Morbidity Endpoint;   Patient Satisfaction;   Throughput Time
11 Unknown  Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes
Conditions: Breast Neoplasms;   Female
Intervention: Biological: blood samples/ ultrasound
Outcome Measures: change in endometrial thickness or uterine volume;   Tolerability of tamoxifen-HRQoL questionnaire;   Vaginal bleeding;   Biochemical changes
12 Recruiting An Observational Study of Hepatitis C Virus in Pregnancy
Condition: Hepatitis C
Intervention:
Outcome Measures: HCV infection of the offspring;   Gestational age at delivery;   Preterm delivery < 37 weeks of gestation;   Gestational diabetes mellitus (GDM);   Vaginal bleeding during pregnancy;   Preeclampsia;   Cholestasis;   Viral load in infant;   HCV antibody status in infant;   Birth weight of infant;   Hyperbilirubinemia;   Neonatal intensive care unit (NICU) admission;   Small for gestational age;   Neonatal infections
13 Unknown  Long Term Outcomes Following Total Laparoscopic Hysterectomy and Laparoscopic Supracervical Hysterectomy
Conditions: Total Laparoscopic Hysterectomy;   Laparoscopic Supracervical Hysterectomy;   Fibromas;   Abnormal Uterine Bleeding;   Dysmenorrhea
Interventions: Procedure: TLH;   Procedure: Laparoscopic supracervical hysterectomy
Outcome Measures: Pelvic pain reduction after the procedure. Occurrence and intensity of pelvic pain after the procedure.;   Patient satisfaction after the procedure;   Occurrence of Vaginal Bleeding after the procedure;   Improvement in patient Quality of Life after the procedure;   Frequency of perioperative and postoperative complications.;   Frequency of menopause;   Frequency of adenomyosis in specimen from the operation.;   Frequency and grade of genital prolapse;   Volume of uterine corpus preoperative, location and size of fibromas, Weight of the removed uterus/uterine corpus.
14 Unknown  Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin
Condition: Uterine Leiomyoma
Interventions: Drug: Dienogest;   Drug: Goserelin;   Drug: Desogestrel
Outcome Measures: Leiomyoma Volume;   Pictorial Blood Assessment Chart (PBAC) Score Reduction;   Number of episodes of vaginal bleeding
15 Recruiting Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding
Condition: Dysfunction Uterine Bleeding
Interventions: Device: Tactile electrosurgical ablation probe;   Device: Hysteroscopic endometrial ablation
Outcome Measures: Satisfaction with the treatment at 12 month follow up;   Change in menstrual status.;   Acceptability of treatment;   Changes in health related quality of life;   Difference in operative time between the two groups in minutes.;   Reporting of any intro-operative complications.;   Reporting of any technical complications.;   Difference in post-operative pain score using visual analogue scale between the two groups.;   Time needed for post operative recovery (days) of pain, Vaginal Bleeding, vaginal discharge, till full recovery and till return to work.;   Length of hospital stay in days;   Difference in the cost of the two surgical procedure.
16 Recruiting A Comparison of Rapid Immunoassays for the Detection of Ruptured Membranes
Condition: Evidence of Ruptured Membranes in Women >15wks Gestation.
Intervention:
Outcome Measure: evidence of ruptured membranes
17 Unknown  Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy
Conditions: Pregnancy;   Vulvovaginitis;   Uterine Cervicitis;   Pregnancy Outcome
Intervention: Other: Active search of lower genital tract infections
Outcome Measure: Track pregnant women priority for the exams that allow the etiologic diagnosis of lower genital tract infections.
18 Unknown  Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage
Condition: Postpartum Hemorrhage
Intervention: Drug: oxygen
Outcome Measures: The primary outcome was the amount of blood loss in the third and fourth stages of labor.;   incidences of Postpartum Haemorrhage (PPH) (≥500 ml)
19 Recruiting Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Comparison of the measures of ovarian reserve (AMH, FSH and E2) to that of health controls;   Degree of change in AMH, FSH, and E2 defined as the ratio of baseline minus end of therapy (EOT) measurement over baseline;   Degree of recovery of AMH, FSH, and E2 in the post-therapy phase;   Rate of AOF
20 Recruiting Newborn Kit to Save Lives in Pakistan
Condition: Neonatal Mortality
Intervention: Device: Neonatal kit
Outcome Measures: Neonatal mortality;   Incidence of omphalitis;   Incidence of severe infection;   Cases of hypothermia identified;   Cases of hyperthermia identified;   Number of low birth weight (LBW) newborns identified;   Health Facility Use;   Neurodevelopmental score at 12 months of age

These studies may lead to new treatments and are adding insight into Vaginal Bleeding etiology and treatment.

A major focus of Vaginal Bleeding research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Vaginal Bleeding